¼¼°èÀÇ ÀǾàǰ Á¦Á¶ ½ÃÀå º¸°í¼­(2025³â)
Pharmaceutical Manufacturing Global Market Report 2025
»óǰÄÚµå : 1760689
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,993,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,765,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀǾàǰ Á¦Á¶ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ±Þ¼ÓÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº °³ÀÎ ¸ÂÃãÇü ÀÇÇÐÀÇ ºÎ»ó, °í·É Àα¸ Áõ°¡, ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Áö¿ª Á¦Á¶¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø, ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¿¬¼Ó Á¦Á¶ÀÇ ¹ßÀü, Àΰø Áö´ÉÀÇ ÅëÇÕ, ½º¸¶Æ® Á¦Á¶ ±â¼úÀÇ Ã¤ÅÃ, »ý¹°ÇÐÀû Á¦Á¦ »ý»êÀÇ Çõ½Å, ¿¬±¸ °³¹ß È¿À²¼º °³¼±¿¡ ´ëÇÑ ÁýÁß µîÀÌ ÀÖ½À´Ï´Ù.

¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÇâÈÄ ¸î ³â µ¿¾È ÀǾàǰ Á¦Á¶ ½ÃÀåÀÇ È®ÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¸¼º ÁúȯÀº ÀϹÝÀûÀ¸·Î ¼­¼­È÷ ÁøÇàµÇ°í 1³â ÀÌ»ó Áö¼ÓµÇ¸ç, Áö¼ÓÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇϰųª ÀÏ»ó »ýȰ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Àå±âÀûÀÎ °Ç°­ »óÅÂÀÔ´Ï´Ù. ¸¸¼º ÁúȯÀÇ Áõ°¡´Â ÁÖ·Î ±â´ë ¼ö¸íÀÇ Áõ°¡, ¾É¾ÆÀÖ´Â »ýȰ ¹æ½Ä, À߸øµÈ ½Ä½À°üÀ¸·Î ÀÎÇØ ¹ß»ýÇϸç, ÀÌ·¯ÇÑ ¿äÀεéÀº ¸ðµÎ Àå±âÀûÀÎ ÀÇ·á ¼Ö·ç¼Ç ¹× ¿¹¹æÀû °Ç°­ °ü¸® Á¶Ä¡¿¡ ´ëÇÑ Çʿ伺À» ³ôÀÔ´Ï´Ù. ÀǾàǰ Á¦Á¶´Â Çʼö ÀǾàǰÀÇ ¾ÈÁ¤Àû °ø±ÞÀ» º¸ÀåÇϰí, ÀǾàǰ °³¹ßÀÇ Çõ½ÅÀ» ÃËÁøÇϸç, È¿°úÀûÀÎ Àå±â Ä¡·á¿¡ ´ëÇÑ Áõ°¡ÇÏ´Â ¼ö¿ä¸¦ ÃæÁ·ÇÔÀ¸·Î½á ¸¸¼º Áúȯ¿¡ ´ëóÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 9¿ù, ¿µ±¹ Á¤ºÎ ±â°üÀÎ ±¹¹Î°Ç°­¼­ºñ½º(NHS)´Â 35¼¼ ÀÌ»ó ¼ºÀÎÀÇ 11%°¡ ÁøÇ༺ ¸¸¼º ½ÅÀå ÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, ±× À¯º´·ü°ú ÁßÁõµµ´Â ¿¬·ÉÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ³ô¾ÆÁø´Ù°í º¸°íÇß½À´Ï´Ù. 75¼¼ ÀÌ»ó Àα¸ÀÇ ¾à 48%°¡ ¾î¶² ÇüÅÂÀÇ ¸¸¼º ÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, 36%´Â ´õ ½É°¢ÇÑ ´Ü°è¿¡ ÀÖ½À´Ï´Ù. µû¶ó¼­ ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϸ鼭 ÀǾàǰ Á¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

ÀǾàǰ Á¦Á¶ ½ÃÀåÀÇ ±â¾÷µéÀº »ý»ê È¿À²¼ºÀ» ³ôÀ̰í, ³ôÀº ǰÁú ±âÁØÀ» º¸ÀåÇϸç, Ç¥Àû ¾Ï Ä¡·á¿¡ ´ëÇÑ Áõ°¡ÇÏ´Â ¼ö¿ä¸¦ ÃæÁ·Çϱâ À§ÇØ ¿ÏÀü ÀÚµ¿È­µÈ RLT Á¦Á¶ ½Ã¼³°ú °°Àº ÷´Ü ¼Ö·ç¼ÇÀ» °³¹ßÇÏ´Â µ¥ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È­µÈ RLT Á¦Á¶ ½Ã¼³Àº ÷´Ü ÀÚµ¿È­ ±â¼úÀ» Ȱ¿ëÇÏ¿© ¹æ»ç¼º ¸®°£µå Ä¡·áÁ¦ÀÇ »ý»êÀ» ÃÖÀûÈ­ÇÏ°í °£¼ÒÈ­ÇÏ¿© ÀϰüµÇ°í È¿À²ÀûÀ̸ç È®Àå °¡´ÉÇÑ Á¦Á¶¸¦ º¸ÀåÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 1¿ù, ½ºÀ§½º¿¡ º»»ç¸¦ µÐ Á¦¾à ȸ»çÀÎ Novartis AG´Â Àεð¾Ö³ªÆú¸®½º¿¡ ÀÖ´Â Ãֽйæ»ç¼º ¸®°£µå Ä¡·áÁ¦(RLT) Á¦Á¶ ½Ã¼³¿¡¼­ Pluvicto¸¦ »ý»êÇÏ´Â °ÍÀ» ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ ½ÂÀι޾ҽÀ´Ï´Ù. ÀÌ È®ÀåÀº Pluvicto ¹× Lutathera¸¦ Æ÷ÇÔÇÑ ¹æ»ç¼º ¸®°£µå Ä¡·áÁ¦ ÀǾàǰÀÇ »ý»ê ´É·ÂÀ» Å©°Ô Çâ»ó½Ãų °ÍÀÔ´Ï´Ù. ÀÌ ¿òÁ÷ÀÓÀº Àü ¼¼°èÀûÀ¸·Î Áõ°¡Çϴ ǥÀû ¾Ï Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃæÁ·ÇÏ°í ¼¼°èÀÇ È¯ÀÚÀÇ Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇÑ NovartisÀÇ ´õ Å« Àü·«ÀÇ ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, Äڷγª 19 ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°, ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Pharmaceutical manufacturing is the industrial process of creating, producing, and packaging medications and medical products at scale, utilizing chemical synthesis, biological processing, and the formulation of active and inactive ingredients. This process is conducted under strict regulatory and quality control standards to ensure the safety, efficacy, consistency, and compliance of drugs intended for both human and veterinary use within global healthcare systems.

The primary molecule types in pharmaceutical manufacturing include biologics, biosimilars, and conventional drugs. Tablets are solid, flat medications containing a specific amount of active ingredients. Other formulations include capsules, injectables, sprays, suspensions, powders, and more, which are administered via various routes such as oral, topical, parenteral, inhalation, and others. Pharmaceutical manufacturing serves a wide range of therapy areas, including cardiovascular diseases (CVDs), pain management, diabetes, cancer, respiratory diseases, and more. These products are distributed through both retail and non-retail sales channels.

The pharmaceutical manufacturing market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical manufacturing market statistics, including the pharmaceutical manufacturing industry's global market size, regional shares, competitors with an pharmaceutical manufacturing market share, detailed pharmaceutical manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical manufacturing industry. This pharmaceutical manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmaceutical manufacturing market size has grown rapidly in recent years. It will grow from $519.78 billion in 2024 to $573.95 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth during the historic period can be attributed to the increasing global disease burden, rising healthcare spending, growing demand for generic drugs, patent expirations of blockbuster drugs, and the expansion of pharmaceutical production capacity.

The pharmaceutical manufacturing market size is expected to see rapid growth in the next few years. It will grow to $846.74 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth during the forecast period can be attributed to the rise of personalized medicine, the expanding elderly population, increasing demand for biosimilars, government support for local manufacturing, and the growing prevalence of chronic diseases. Key trends in the forecast period include advancements in continuous manufacturing, the integration of artificial intelligence, the adoption of smart manufacturing technologies, innovations in biologics production, and a focus on improving research and development efficiency.

The growing prevalence of chronic diseases is expected to drive the expansion of the pharmaceutical manufacturing market in the coming years. Chronic diseases are long-term health conditions that typically develop gradually and persist for a year or more, often requiring ongoing medical care or impacting daily activities. The rise in chronic diseases is largely due to increasing life expectancy, sedentary lifestyles, and poor dietary habits, all contributing to a greater need for long-term healthcare solutions and preventive wellness measures. Pharmaceutical manufacturing plays a crucial role in addressing chronic diseases by ensuring a steady supply of essential medications, fostering innovation in drug development, and meeting the rising demand for effective long-term treatments. For example, in September 2024, the National Health Service (NHS), a UK government organization, reported that 11% of adults aged 35 and older have advanced chronic kidney disease, with the prevalence and severity increasing with age. Nearly 48% of individuals aged 75 and above suffer from some form of the disease, and 36% have more severe stages. Thus, the growing prevalence of chronic diseases is driving growth in the pharmaceutical manufacturing market.

Major companies in the pharmaceutical manufacturing market are concentrating on developing advanced solutions, such as fully automated RLT manufacturing facilities, to boost production efficiency, ensure high-quality standards, and address the rising demand for targeted cancer therapies. An automated RLT manufacturing facility utilizes advanced automation technologies to optimize and streamline the production of radioligand therapies, ensuring consistent, efficient, and scalable manufacturing. For example, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) to produce Pluvicto at a cutting-edge radioligand therapy (RLT) manufacturing facility in Indianapolis. This expansion will significantly enhance the production capacity for its radioligand therapy medicines, including Pluvicto and Lutathera. This move is part of Novartis' larger strategy to meet the growing global demand for targeted cancer therapies and improve patient access worldwide.

In December 2024, Novo Holdings A/S, a Denmark-based asset management company, acquired Catalent for $16.5 billion. This acquisition allows Novo Holdings to strengthen its position in the life sciences sector by leveraging Catalent's leading expertise in drug development, manufacturing, and clinical supply management. The move aims to accelerate growth, improve patient outcomes, and create sustainable value within the pharmaceutical and biotechnology industries. Catalent Inc. is a US-based pharmaceutical company that offers pharmaceutical manufacturing services.

Major players in the pharmaceutical manufacturing market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Inc., Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Lonza Group AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, Cipla Limited, Samsung Biologics, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Lupin Limited, and Jubilant Pharmova Limited.

North America was the largest region in the pharmaceutical manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharmaceutical manufacturing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pharmaceutical manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharmaceutical manufacturing market consists of revenues earned by entities by providing services such as contract manufacturing, formulation development, quality control and testing, and packaging and labeling. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical manufacturing market also includes sales of syrups, patch formulations, biologics, and antibiotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharmaceutical Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharmaceutical manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pharmaceutical manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pharmaceutical manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Pharmaceutical Manufacturing Market Characteristics

3. Pharmaceutical Manufacturing Market Trends And Strategies

4. Pharmaceutical Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pharmaceutical Manufacturing Growth Analysis And Strategic Analysis Framework

6. Pharmaceutical Manufacturing Market Segmentation

7. Pharmaceutical Manufacturing Market Regional And Country Analysis

8. Asia-Pacific Pharmaceutical Manufacturing Market

9. China Pharmaceutical Manufacturing Market

10. India Pharmaceutical Manufacturing Market

11. Japan Pharmaceutical Manufacturing Market

12. Australia Pharmaceutical Manufacturing Market

13. Indonesia Pharmaceutical Manufacturing Market

14. South Korea Pharmaceutical Manufacturing Market

15. Western Europe Pharmaceutical Manufacturing Market

16. UK Pharmaceutical Manufacturing Market

17. Germany Pharmaceutical Manufacturing Market

18. France Pharmaceutical Manufacturing Market

19. Italy Pharmaceutical Manufacturing Market

20. Spain Pharmaceutical Manufacturing Market

21. Eastern Europe Pharmaceutical Manufacturing Market

22. Russia Pharmaceutical Manufacturing Market

23. North America Pharmaceutical Manufacturing Market

24. USA Pharmaceutical Manufacturing Market

25. Canada Pharmaceutical Manufacturing Market

26. South America Pharmaceutical Manufacturing Market

27. Brazil Pharmaceutical Manufacturing Market

28. Middle East Pharmaceutical Manufacturing Market

29. Africa Pharmaceutical Manufacturing Market

30. Pharmaceutical Manufacturing Market Competitive Landscape And Company Profiles

31. Pharmaceutical Manufacturing Market Other Major And Innovative Companies

32. Global Pharmaceutical Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pharmaceutical Manufacturing Market

34. Recent Developments In The Pharmaceutical Manufacturing Market

35. Pharmaceutical Manufacturing Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â